Follicle-Stimulating Hormone (FSH): Physiology and What Studies Report

Follicle-stimulating hormone (FSH) is one of the two gonadotropins secreted by the anterior pituitary gland, alongside luteinising hormone (LH). Reference physiology reviews classify it as a glycoprotein hormone built from a shared alpha subunit and a hormone-specific beta subunit, and describe its release as being governed by hypothalamic gonadotropin-releasing hormone together with gonadal feedback signals (Physiology, Pituitary Hormones). A dedicated physiology review of FSH described its principal targets as granulosa cells in the ovary and Sertoli cells in the testis, where it supports gamete development (Physiology, Follicle Stimulating Hormone).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any hormone, medication or laboratory test. Nothing here describes a protocol, and no dosing information is provided.

Where FSH Fits in the Endocrine Map

How the Pituitary Controls FSH Synthesis

FSH output is not simply a mirror of GnRH pulses. Work on the activin–SMAD pathway examined gonadotrope-specific signalling and reported that SMAD3 regulates FSH synthesis by pituitary gonadotrope cells in vivo, placing transcriptional control of the FSH beta subunit downstream of TGF-beta family inputs (SMAD3 Regulates Follicle-stimulating Hormone Synthesis by Pituitary Gonadotrope Cells in Vivo).

A 2025 study extended that picture beyond the gonads. The researchers reported that muscle-derived myostatin acts as a major endocrine driver of FSH synthesis, describing a skeletal-muscle-to-pituitary signal feeding into the same TGF-beta family machinery (Muscle-derived myostatin is a major endocrine driver of follicle-stimulating hormone synthesis). That finding is laboratory physiology rather than a clinical intervention, and the study did not establish a therapeutic use.

The FSH Receptor

FSH signals through the FSH receptor (FSHR). A review of receptor behaviour described FSHR trans-activation and oligomerisation, meaning that receptor molecules can associate with one another and that signalling can occur through arrangements more complex than one hormone binding one isolated receptor (FSHR Trans-Activation and Oligomerization). This receptor biology is one reason investigators have looked for FSHR expression outside the gonads.

FSH in Female Reproductive Physiology

In the ovary, FSH is described as the signal that recruits and grows antral follicles, with granulosa cells converting androgens to oestradiol. A review of the morphology and biochemistry of ovulation set out the sequence in which follicular development precedes the mid-cycle gonadotropin surge that triggers oocyte release and luteinisation (Morphology and Biochemistry of Ovulation). The physiology reference likewise describes rising FSH in the early follicular phase and feedback suppression as oestradiol and inhibin rise (PMID 30571063).

Because ovarian feedback falls away at menopause, circulating FSH rises. Commentary literature has treated that rise as a possible signal in its own right rather than only a marker, and has asked whether FSH contributes to post-menopausal changes in bone and fat (Burning Fat and Building Bone by FSH Blockade).

FSH in Male Reproductive Physiology

In males, FSH acts on Sertoli cells to support spermatogenesis, while LH drives Leydig cell testosterone production (PMID 30571063). Exogenous testosterone suppresses pituitary gonadotropins, and a 2025 fertility study examined regimens intended to restore spermatogenesis after testosterone therapy using human chorionic gonadotropin together with follicle-stimulating hormone; the researchers reported on the combination's role in recovery of sperm production (Optimal restoration of spermatogenesis after testosterone therapy using human chorionic gonadotropin and follicle-stimulating hormone). That work concerns prescription fertility management under clinician supervision and is summarised here only as published evidence.

FSH, Bone and Fat: What Studies Report

The most discussed non-reproductive FSH literature comes from animal work. A 2017 Nature study reported that blocking FSH with an antibody induced thermogenic adipose tissue and reduced body fat in mice (Blocking FSH induces thermogenic adipose tissue and reduces body fat). An accompanying commentary framed the same approach as simultaneously affecting fat and bone, under the heading of burning fat and building bone by FSH blockade (PMID 28768167).

A later Chinese-language review summarised these strands as new roles for FSH in metabolic regulation and aging, describing reported associations between FSH and adiposity, bone loss and age-related change (Follicle-stimulating hormone: new roles in metabolic regulation and aging). A separate commentary asked directly whether FSH can influence longevity, treating the question as open rather than answered (Can FSH influence longevity?).

Important limits on that evidence

• The thermogenic fat findings were reported in mice, not in humans (PMID 28538730).
• The longevity discussion was hypothesis-generating commentary, not an outcome trial (PMID 28856803).
• FSH-blocking antibodies described in that literature are research tools, not approved products (PMID 28768167).

FSH and Cancer Signalling: What Studies Report

Because FSHR has been detected outside the gonads, investigators have examined FSH in tumour biology. A 2026 review of follicle-stimulating hormone and cancer summarised reported FSH–FSHR signalling in tumour and tumour-associated vascular tissue and discussed its proposed relevance as a biomarker and target (Follicle-stimulating hormone and cancer). The review is a synthesis of preclinical and observational work rather than evidence of a treatment effect.

Adverse Events and Safety Signals: What Studies Report

The verified literature summarised on this page is largely physiological and preclinical, and it does not provide a human safety profile for FSH modulation outside approved fertility care. The mouse antibody work reported metabolic and skeletal changes as outcomes of interest rather than a full toxicology assessment (PMID 28538730), and the commentary on that approach noted that translating FSH blockade into humans remained an open question (PMID 28768167). Clinical use of gonadotropins in fertility settings is prescription-only and monitored by physicians, as reflected in the spermatogenesis-recovery literature (PMID 39442683).

What Remains Unsettled

1. Whether the metabolic effects reported after FSH blockade in mice occur in humans (PMID 28538730).
2. How much of the post-menopausal change attributed to oestrogen loss is instead attributable to high FSH (PMID 34708232).
3. Whether muscle-derived myostatin signalling to the pituitary has clinical implications (PMID 39818879).
4. Whether FSHR signalling described in tumour contexts is causal or associative (PMID 42442675).

References

• Physiology, Pituitary Hormones (StatPearls, 2026)
• Physiology, Follicle Stimulating Hormone (StatPearls, 2026)
• SMAD3 Regulates Follicle-stimulating Hormone Synthesis by Pituitary Gonadotrope Cells in Vivo (The Journal of Biological Chemistry, 2017)
• Muscle-derived myostatin is a major endocrine driver of follicle-stimulating hormone synthesis (Science, 2025)
• FSHR Trans-Activation and Oligomerization (Frontiers in Endocrinology, 2018)
• Morphology and Biochemistry of Ovulation (Revista Brasileira de Ginecologia e Obstetricia, 2021)
• Optimal restoration of spermatogenesis after testosterone therapy using human chorionic gonadotropin and follicle-stimulating hormone (Fertility and Sterility, 2025)
• Blocking FSH induces thermogenic adipose tissue and reduces body fat (Nature, 2017)
• Burning Fat and Building Bone by FSH Blockade (Cell Metabolism, 2017)
• Can FSH influence longevity? (Aging Cell, 2017)
• Follicle-stimulating hormone: new roles in metabolic regulation and aging (Acta Physiologica Sinica, 2021)
• Follicle-stimulating hormone and cancer (Cellular Signalling, 2026)